COVID-19 and healthcare workers: A systematic review and meta-analysis.


Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 11 11 2020
revised: 05 01 2021
accepted: 06 01 2021
pubmed: 15 1 2021
medline: 12 5 2021
entrez: 14 1 2021
Statut: ppublish

Résumé

The COVID-19 pandemic has focused attention on the challenges and risks faced by frontline healthcare workers (HCW). This study aimed to describe the clinical outcomes and risk factors for SARS-CoV-2 infection in HCW. Three databases were surveyed and 328 articles were identified. Of these, 225 articles did not meet inclusion criteria; therefore, 97 full-text article were reviewed. Finally, after further revision, 30 articles were included in the systematic review and 28 were used for meta-analysis. Twenty-eight studies were identified involving 119,883 patients. The mean age of the patients was 38.37 years (95% CI 36.72-40.03) and males comprised 21.4% (95% CI 12.4-34.2) of the population of HCW. The percentage of HCW who tested positive for COVID-19 was 51.7% (95% CI 34.7-68.2). The total prevalence of comorbidities in seven studies was 18.4% (95% CI 15.5-21.7). The most prevalent symptoms were fever 27.5% (95% CI 17.6-40.3) and cough 26.1% (95% CI 18.1-36). The prevalence of hospitalisation was 15.1% (95% CI 5.6-35) in 13 studies and of death was 1.5% (95% CI 0.5-3.9) in 12 studies. Comparisons of HCW with and without infection showed an increased relative risk for COVID-19 related to personal protective equipment, workplace setting, profession, exposure, contacts, and testing. A significant number of HCW were reported to be infected with COVID-19 during the first 6 months of the COVID-19 pandemic, with a prevalence of hospitalisation of 15.1% and mortality of 1.5%. Further data are needed to track the continued risks in HCW as the pandemic evolves and health systems adapt.

Sections du résumé

BACKGROUND BACKGROUND
The COVID-19 pandemic has focused attention on the challenges and risks faced by frontline healthcare workers (HCW). This study aimed to describe the clinical outcomes and risk factors for SARS-CoV-2 infection in HCW.
METHODS METHODS
Three databases were surveyed and 328 articles were identified. Of these, 225 articles did not meet inclusion criteria; therefore, 97 full-text article were reviewed. Finally, after further revision, 30 articles were included in the systematic review and 28 were used for meta-analysis.
RESULTS RESULTS
Twenty-eight studies were identified involving 119,883 patients. The mean age of the patients was 38.37 years (95% CI 36.72-40.03) and males comprised 21.4% (95% CI 12.4-34.2) of the population of HCW. The percentage of HCW who tested positive for COVID-19 was 51.7% (95% CI 34.7-68.2). The total prevalence of comorbidities in seven studies was 18.4% (95% CI 15.5-21.7). The most prevalent symptoms were fever 27.5% (95% CI 17.6-40.3) and cough 26.1% (95% CI 18.1-36). The prevalence of hospitalisation was 15.1% (95% CI 5.6-35) in 13 studies and of death was 1.5% (95% CI 0.5-3.9) in 12 studies. Comparisons of HCW with and without infection showed an increased relative risk for COVID-19 related to personal protective equipment, workplace setting, profession, exposure, contacts, and testing.
CONCLUSION CONCLUSIONS
A significant number of HCW were reported to be infected with COVID-19 during the first 6 months of the COVID-19 pandemic, with a prevalence of hospitalisation of 15.1% and mortality of 1.5%. Further data are needed to track the continued risks in HCW as the pandemic evolves and health systems adapt.

Identifiants

pubmed: 33444754
pii: S1201-9712(21)00023-0
doi: 10.1016/j.ijid.2021.01.013
pmc: PMC7798435
pii:
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

335-346

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Références

J Clin Invest. 2020 Sep 1;130(9):4726-4733
pubmed: 32463802
J Microbiol Immunol Infect. 2021 Feb;54(1):54-60
pubmed: 32359943
JAMA. 2020 May 26;323(20):2087-2089
pubmed: 32301962
Med Lav. 2020 Jun 26;111(3):184-194
pubmed: 32624560
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Int J Infect Dis. 2021 Jan;102:239-241
pubmed: 33130210
Invest Radiol. 2020 Jun;55(6):327-331
pubmed: 32118615
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
JAMA Netw Open. 2020 May 1;3(5):e209666
pubmed: 32437575
JAMA Netw Open. 2020 May 1;3(5):e209673
pubmed: 32437576
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Clin Infect Dis. 2020 Nov 19;71(16):2109-2113
pubmed: 32409825
J Clin Virol. 2020 Jul;128:104437
pubmed: 32434708
J Med Virol. 2020 Apr;92(4):424-432
pubmed: 31981224
Swiss Med Wkly. 2020 Apr 25;150:w20257
pubmed: 32333603
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Lancet. 2020 May 2;395(10234):1418-1420
pubmed: 32305073
Clin Infect Dis. 2020 Nov 19;71(16):2218-2221
pubmed: 32179890
Indian J Occup Environ Med. 2009 Aug;13(2):77-9
pubmed: 20386623
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
J Community Health. 2020 Aug;45(4):675-683
pubmed: 32440724
J Med Virol. 2020 Jul;92(7):807-813
pubmed: 32222986
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Mil Med Res. 2020 May 11;7(1):24
pubmed: 32393381
SN Compr Clin Med. 2020 Jun 25;:1-8
pubmed: 32838147
Euro Surveill. 2020 Mar;25(12):
pubmed: 32234115
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):477-481
pubmed: 32298247
PLoS One. 2018 Nov 15;13(11):e0206831
pubmed: 30439974
N Engl J Med. 2020 May 21;382(21):2005-2011
pubmed: 32220208
Curr Med Sci. 2020 Apr;40(2):295-300
pubmed: 32232652
J Infect Public Health. 2020 Jun;13(6):843-848
pubmed: 32493671
Int J Environ Res Public Health. 2020 Jun 16;17(12):
pubmed: 32560180
J Bone Joint Surg Am. 2020 May 20;102(10):847-854
pubmed: 32271208
MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):377-381
pubmed: 32240128
Res Social Adm Pharm. 2021 Jan;17(1):1882-1887
pubmed: 32499159
J Med Virol. 2020 Jun;92(6):612-617
pubmed: 32108351
N Engl J Med. 2020 Jun 4;382(23):2267-2268
pubmed: 32294342
J Infect Public Health. 2020 Mar;13(3):418-422
pubmed: 31056437
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):472-476
pubmed: 32298249
Lancet Public Health. 2020 Sep;5(9):e475-e483
pubmed: 32745512
Clin Infect Dis. 2021 Jan 27;72(2):265-270
pubmed: 33501962
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183934
Euro Surveill. 2020 Apr;25(16):
pubmed: 32347200

Auteurs

Mandana Gholami (M)

College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Healthcare City, Dubai, United Arab Emirates.

Iman Fawad (I)

College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Healthcare City, Dubai, United Arab Emirates.

Sidra Shadan (S)

College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Healthcare City, Dubai, United Arab Emirates.

Rashed Rowaiee (R)

College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Healthcare City, Dubai, United Arab Emirates.

HedaietAllah Ghanem (H)

College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Healthcare City, Dubai, United Arab Emirates.

Amar Hassan Khamis (A)

Hamdan Bin Mohammed College of Dental Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Healthcare City, Dubai, United Arab Emirates.

Samuel B Ho (SB)

College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Healthcare City, Dubai, United Arab Emirates; Department of Medicine, Mediclinic City Hospital, Dubai Healthcare City, Dubai, United Arab Emirates. Electronic address: samuel.ho@mbru.ac.ae.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH